Core Viewpoint - Kolun Botai Biotech-B announced a new share placement to raise approximately $250 million, marking the largest new share issuance in the Hong Kong biopharmaceutical sector in the past 12 months [1][2]. Group 1: Share Placement Details - The company plans to issue 5.918 million H-shares at a price of HKD 331.8 per share, which represents about 2.54% of the total share capital post-issuance [1][2]. - The placement price reflects a discount of approximately 7.58% from the previous day's closing price of HKD 359, while it shows a premium of 0.89% compared to the average price over the last five days [2]. - The placement has received strong interest from domestic and international investors, leading to an increase in the transaction size from the initially planned $200 million to $250 million due to high demand [2]. Group 2: Use of Proceeds - The funds raised will primarily be allocated for product research and development, clinical trials, regulatory filings, manufacturing, and commercialization efforts [2]. - The financing aims to enhance the company's internal R&D capabilities, strengthen external collaborations, and expand its product pipeline [2]. Group 3: Previous Fundraising Activities - In May 2024, the company completed a previous share placement at HKD 150 per share, raising approximately HKD 541 million [3]. - The total funds raised from the two placements and a directed issuance amount to nearly HKD 3 billion [4]. - The company has also secured upfront payments from an authorized transaction related to a drug for respiratory diseases, which could yield up to $970 million in milestone payments and royalties [4].
科伦博泰2.5亿美元配售背后：创新药研发“烧钱”不止，港股医药行情火热